Extended autoantibody panel in Turkish patients with early‐stage systemic sclerosis: Coexpressions and their influences on clinical phenotypes
Abstract Background/Aim To investigate the frequency and clinical relevance of an extended autoantibody profile in patients with systemic sclerosis (SSc). Materials and Methods In this cross‐sectional study, serum from 100 consecutive patients was subjected to indirect immunofluorescence (IIF) (HEp‐...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-12-01
|
| Series: | Immunity, Inflammation and Disease |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/iid3.1089 |
| _version_ | 1827395777036550144 |
|---|---|
| author | Duygu Temiz Karadağ Andac Komac Yesim Erez Ahmet Merih Birlik Alper Sari Ali Akdoğan Bayram Farisogullari Gezmiş Kimyon Emrah Koc Didem Arslan Ahmet Karatas Suleyman Serdar Koca Nilgün Kasifoglu Ayten Yazici Kadir Mutlu Hayran Ayse Cefle |
| author_facet | Duygu Temiz Karadağ Andac Komac Yesim Erez Ahmet Merih Birlik Alper Sari Ali Akdoğan Bayram Farisogullari Gezmiş Kimyon Emrah Koc Didem Arslan Ahmet Karatas Suleyman Serdar Koca Nilgün Kasifoglu Ayten Yazici Kadir Mutlu Hayran Ayse Cefle |
| author_sort | Duygu Temiz Karadağ |
| collection | DOAJ |
| description | Abstract Background/Aim To investigate the frequency and clinical relevance of an extended autoantibody profile in patients with systemic sclerosis (SSc). Materials and Methods In this cross‐sectional study, serum from 100 consecutive patients was subjected to indirect immunofluorescence (IIF) (HEp‐20‐10/primate liver mosaic) and Systemic Sclerosis Profile by EUROIMMUN to evaluate anti‐nuclear antibodies (ANA) and autoantibodies against 13 different autoantibodies in patients with SSc less than 3 years. Results Ninety‐three of 100 patients were positive for ANA by IIF. Fifty‐three patients showed single positivity, 26 anti‐topoisomerase antibodies (anti‐Scl70 ab), 16 anticentromere antibodies (ACAs), six anti‐RNA polymerase III antibodies (anti‐RNAPIII ab), one anti‐Ku antibody, one anti‐PM/Scl100 antibody, two anti‐PM/Scl75 antibodies, one anti‐Ro52 antibody, whereas 32 patients had multiple autoantibody positivities. Among classic SSc‐specific autoantibodies, anti‐Scl70 and anti‐RNAPIII abs showed the highest cooccurrence (n = 4). One patient was simultaneously positive for anti‐RNAPIII ab and ACA, and one was positive for ACA and anti‐Scl70 ab. The clinical features were not statistically different between single and multiple autoantibody‐positivity for classic SSc‐specific autoantibodies (ACA, anti‐Scl70 ab, and anti‐RNAPIII ab), except for digital ulcer in the multiantibody positive ACA group (p = .019). Conclusion Based on our results, coexpression of autoantibodies is not uncommon in SSc patients. Although autoantibodies specific to SSc in early disease show generally known clinical features, it remains to be investigated how the coexpression of autoantibodies will affect clinical presentation. |
| first_indexed | 2024-03-08T18:39:41Z |
| format | Article |
| id | doaj.art-2eb852870123488ea2e318bed2794123 |
| institution | Directory Open Access Journal |
| issn | 2050-4527 |
| language | English |
| last_indexed | 2024-03-08T18:39:41Z |
| publishDate | 2023-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Immunity, Inflammation and Disease |
| spelling | doaj.art-2eb852870123488ea2e318bed27941232023-12-29T08:52:36ZengWileyImmunity, Inflammation and Disease2050-45272023-12-011112n/an/a10.1002/iid3.1089Extended autoantibody panel in Turkish patients with early‐stage systemic sclerosis: Coexpressions and their influences on clinical phenotypesDuygu Temiz Karadağ0Andac Komac1Yesim Erez2Ahmet Merih Birlik3Alper Sari4Ali Akdoğan5Bayram Farisogullari6Gezmiş Kimyon7Emrah Koc8Didem Arslan9Ahmet Karatas10Suleyman Serdar Koca11Nilgün Kasifoglu12Ayten Yazici13Kadir Mutlu Hayran14Ayse Cefle15Department of Rheumatology Faculty of Medicine, Kocaeli University Kocaeli TurkeyDepartment of Rheumatology Faculty of Medicine, Kocaeli University Kocaeli TurkeyDepartment of Rheumatology Faculty of Medicine, Dokuz Eylül University İzmir TurkeyDepartment of Rheumatology Faculty of Medicine, Dokuz Eylül University İzmir TurkeyDepartment of Rheumatology Faculty of Medicine, Hacettepe University Ankara TurkeyDepartment of Rheumatology Faculty of Medicine, Hacettepe University Ankara TurkeyDepartment of Rheumatology Faculty of Medicine, Hacettepe University Ankara TurkeyDepartment of Rheumatology Faculty of Medicine, Hatay Mustafa Kemal University Hatay TurkeyDepartment of Rheumatology Adana Faculty of Medicine, Cukurova University Adana TurkeyDepartment of Rheumatology Adana Faculty of Medicine, Cukurova University Adana TurkeyDepartment of Rheumatology Faculty of Medicine, Firat University Elazig TurkeyDepartment of Rheumatology Faculty of Medicine, Firat University Elazig TurkeyDepartment of Microbiology Faculty of Medicine, Eskisehir Osmangazi University Eskisehir TurkeyDepartment of Rheumatology Faculty of Medicine, Kocaeli University Kocaeli TurkeyDepartment of Preventive Oncology Faculty of Medicine, Hacettepe University Ankara TurkeyDepartment of Rheumatology Faculty of Medicine, Kocaeli University Kocaeli TurkeyAbstract Background/Aim To investigate the frequency and clinical relevance of an extended autoantibody profile in patients with systemic sclerosis (SSc). Materials and Methods In this cross‐sectional study, serum from 100 consecutive patients was subjected to indirect immunofluorescence (IIF) (HEp‐20‐10/primate liver mosaic) and Systemic Sclerosis Profile by EUROIMMUN to evaluate anti‐nuclear antibodies (ANA) and autoantibodies against 13 different autoantibodies in patients with SSc less than 3 years. Results Ninety‐three of 100 patients were positive for ANA by IIF. Fifty‐three patients showed single positivity, 26 anti‐topoisomerase antibodies (anti‐Scl70 ab), 16 anticentromere antibodies (ACAs), six anti‐RNA polymerase III antibodies (anti‐RNAPIII ab), one anti‐Ku antibody, one anti‐PM/Scl100 antibody, two anti‐PM/Scl75 antibodies, one anti‐Ro52 antibody, whereas 32 patients had multiple autoantibody positivities. Among classic SSc‐specific autoantibodies, anti‐Scl70 and anti‐RNAPIII abs showed the highest cooccurrence (n = 4). One patient was simultaneously positive for anti‐RNAPIII ab and ACA, and one was positive for ACA and anti‐Scl70 ab. The clinical features were not statistically different between single and multiple autoantibody‐positivity for classic SSc‐specific autoantibodies (ACA, anti‐Scl70 ab, and anti‐RNAPIII ab), except for digital ulcer in the multiantibody positive ACA group (p = .019). Conclusion Based on our results, coexpression of autoantibodies is not uncommon in SSc patients. Although autoantibodies specific to SSc in early disease show generally known clinical features, it remains to be investigated how the coexpression of autoantibodies will affect clinical presentation.https://doi.org/10.1002/iid3.1089autoantibodyimmunoblot assayindirect immunofluorescence assayscleroderma‐specific antibodiessystemic sclerosis |
| spellingShingle | Duygu Temiz Karadağ Andac Komac Yesim Erez Ahmet Merih Birlik Alper Sari Ali Akdoğan Bayram Farisogullari Gezmiş Kimyon Emrah Koc Didem Arslan Ahmet Karatas Suleyman Serdar Koca Nilgün Kasifoglu Ayten Yazici Kadir Mutlu Hayran Ayse Cefle Extended autoantibody panel in Turkish patients with early‐stage systemic sclerosis: Coexpressions and their influences on clinical phenotypes Immunity, Inflammation and Disease autoantibody immunoblot assay indirect immunofluorescence assay scleroderma‐specific antibodies systemic sclerosis |
| title | Extended autoantibody panel in Turkish patients with early‐stage systemic sclerosis: Coexpressions and their influences on clinical phenotypes |
| title_full | Extended autoantibody panel in Turkish patients with early‐stage systemic sclerosis: Coexpressions and their influences on clinical phenotypes |
| title_fullStr | Extended autoantibody panel in Turkish patients with early‐stage systemic sclerosis: Coexpressions and their influences on clinical phenotypes |
| title_full_unstemmed | Extended autoantibody panel in Turkish patients with early‐stage systemic sclerosis: Coexpressions and their influences on clinical phenotypes |
| title_short | Extended autoantibody panel in Turkish patients with early‐stage systemic sclerosis: Coexpressions and their influences on clinical phenotypes |
| title_sort | extended autoantibody panel in turkish patients with early stage systemic sclerosis coexpressions and their influences on clinical phenotypes |
| topic | autoantibody immunoblot assay indirect immunofluorescence assay scleroderma‐specific antibodies systemic sclerosis |
| url | https://doi.org/10.1002/iid3.1089 |
| work_keys_str_mv | AT duygutemizkaradag extendedautoantibodypanelinturkishpatientswithearlystagesystemicsclerosiscoexpressionsandtheirinfluencesonclinicalphenotypes AT andackomac extendedautoantibodypanelinturkishpatientswithearlystagesystemicsclerosiscoexpressionsandtheirinfluencesonclinicalphenotypes AT yesimerez extendedautoantibodypanelinturkishpatientswithearlystagesystemicsclerosiscoexpressionsandtheirinfluencesonclinicalphenotypes AT ahmetmerihbirlik extendedautoantibodypanelinturkishpatientswithearlystagesystemicsclerosiscoexpressionsandtheirinfluencesonclinicalphenotypes AT alpersari extendedautoantibodypanelinturkishpatientswithearlystagesystemicsclerosiscoexpressionsandtheirinfluencesonclinicalphenotypes AT aliakdogan extendedautoantibodypanelinturkishpatientswithearlystagesystemicsclerosiscoexpressionsandtheirinfluencesonclinicalphenotypes AT bayramfarisogullari extendedautoantibodypanelinturkishpatientswithearlystagesystemicsclerosiscoexpressionsandtheirinfluencesonclinicalphenotypes AT gezmiskimyon extendedautoantibodypanelinturkishpatientswithearlystagesystemicsclerosiscoexpressionsandtheirinfluencesonclinicalphenotypes AT emrahkoc extendedautoantibodypanelinturkishpatientswithearlystagesystemicsclerosiscoexpressionsandtheirinfluencesonclinicalphenotypes AT didemarslan extendedautoantibodypanelinturkishpatientswithearlystagesystemicsclerosiscoexpressionsandtheirinfluencesonclinicalphenotypes AT ahmetkaratas extendedautoantibodypanelinturkishpatientswithearlystagesystemicsclerosiscoexpressionsandtheirinfluencesonclinicalphenotypes AT suleymanserdarkoca extendedautoantibodypanelinturkishpatientswithearlystagesystemicsclerosiscoexpressionsandtheirinfluencesonclinicalphenotypes AT nilgunkasifoglu extendedautoantibodypanelinturkishpatientswithearlystagesystemicsclerosiscoexpressionsandtheirinfluencesonclinicalphenotypes AT aytenyazici extendedautoantibodypanelinturkishpatientswithearlystagesystemicsclerosiscoexpressionsandtheirinfluencesonclinicalphenotypes AT kadirmutluhayran extendedautoantibodypanelinturkishpatientswithearlystagesystemicsclerosiscoexpressionsandtheirinfluencesonclinicalphenotypes AT aysecefle extendedautoantibodypanelinturkishpatientswithearlystagesystemicsclerosiscoexpressionsandtheirinfluencesonclinicalphenotypes |